New drug combo targets Hard-to-Treat cancers
NCT ID NCT05007782
First seen Jan 03, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug called denikitug, alone or with another cancer drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 416 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
RECRUITINGTaoyuan City, 33308, Taiwan
-
Changhua Christian Hospital
RECRUITINGChanghua, 500, Taiwan
-
Chi Mei Hospital, Liouying
RECRUITINGTainan, 73657, Taiwan
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Clinica Universidad de Navarra
RECRUITINGPamplona, 31008, Spain
-
Hospital Universitari Vall d´Hebrón
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Quironsalud Madrid
RECRUITINGMadrid, 28223, Spain
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
MD Anderson Cancer Center
RECRUITINGMadrid, 28033, Spain
-
Monash Medical Centre
RECRUITINGClayton, Victoria, 3168, Australia
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
National Taiwan University Cancer Center (NTUCC)
RECRUITINGTaipei, 100229, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, 100, Taiwan
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Sarah Cannon Research Institute at Mary Crowley
RECRUITINGDallas, Texas, 75230, United States
-
Smilow Cancer Center
COMPLETEDNew Haven, Connecticut, 06510, United States
-
Stanford Cancer Center
RECRUITINGPalo Alto, California, 94305, United States
-
Taipei Tzu Chi General Hospital
WITHDRAWNTaipei, 110, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 11217, Taiwan
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States
-
University Health Network, Princess Margaret Cancer Centre
RECRUITINGToronto, M5G 2M9, Canada
-
University of California San Diego
RECRUITINGLa Jolla, California, 92093, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 39090, United States
-
University of Wisconsin Clinical Sciences Center
RECRUITINGMadison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.